Application of therapeutic protein-based fusion toxins

In this study, we review the recent therapeutic trials and improvements of fusion protein toxins.Recent findingsAs a targeting moiety, non-Ig scaffolds have not only the advantages of immunoglobulin such as high affinity and selectivity, but also small size, high stability, high yield expression. As a toxic moiety, non-immunologic and highly toxic endogenous proteins of human origin like proapoptotic protein or RNase are challenged. To lessen the adverse reactions of fusion toxins, several therapeutic strategies such as removal of epitopes, increase of serum half-life were developed.
Source: Molecular and Cellular Toxicology - Category: Cytology Source Type: research